To identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines.

Ended Definitive Contract Awarded Last action

Contract number
75N93019C00041
Awardee
Awarding agency
Obligated
$9,981,722

Award facts

Opportunity
Contract value 100% obligated
$9,981,721.80 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 12 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Chicago, IL 60637, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00015 · To administrate DE-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 -$1,746
Change Order P00014 $1,027,798
Funding Only Action P00013 -$66
Other Administrative Action P00012 $0
Exercise an Option P00011 $1,449,134
Other Administrative Action P00010 $0
Exercise an Option P00009 $1,387,684
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Exercise an Option P00004 $1,977,288
Other Administrative Action P00003 $0
Exercise an Option P00002 · Exercise OPT 1. To identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. $1,347,932
Change Order P00001 · Covid-19. To identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. $319,510
Original award $2,474,188
Show all 16

About this award

Written by GovTribe AI ·

The National Institute of Allergy and Infectious Diseases awarded a definitive contract to The University of Chicago for vaccine adjuvant discovery on September 30, 2019, with a ceiling value of $9,981,721.80 under cost, no-fee pricing and ultimate completion date of April 30, 2026.

The originating solicitation, posted January 17, 2018, addresses identification of novel adjuvant candidates to augment human vaccine efficacy. The work focuses on discovering and optimizing small-molecule immune modulators that enhance innate immune activation and T-cell responses during vaccination, with specific attention to controlling excess inflammation. Formulations will be tested for compatibility with current quadrivalent vaccines and next-generation vaccine platforms, targeting improved reactogenicity, reduced dosage, and increased durability while maintaining appropriate toxicity and safety profiles. Place of performance is Chicago, IL.

Service Contract Inventory data reflects actual government-invoiced figures: FY2021 invoiced $760 thousand across 1.1 FTEs and 2,340 contractor hours at a derived rate of $324.91 per hour; FY2022 invoiced $2.4 million across 4.5 FTEs and 9,434 contractor hours at $257.91 per hour. The prime self-performed all reported hours with no subcontractors reported in FY2022. Government-paid hourly rates declined year-over-year. Valjuvant Corporation, a minority-owned small disadvantaged business, performed vaccine adjuvant formulation work as a subcontractor.

Subawards

Subcontractor Amount Awarded
Valjuvant Corporation TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. 3.1 Scope In this project, we propose to develop new… $214,999

Quick answers

Who was awarded contract 75N93019C00041?

75N93019C00041 was awarded to The University Of Chicago by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2019.

How much is contract 75N93019C00041 worth?

The government has obligated $9,981,722 on 75N93019C00041.

Was contract 75N93019C00041 competed?

The extent of competition for 75N93019C00041 was full and open competition. The government received 12 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login